Cargando…
Harnessing allogeneic CD4(+) T cells to reinvigorate host endogenous antitumor immunity
Immune checkpoint blockade (ICB) therapies developed over the past decade have been among the most promising approaches for the treatment of patients with advanced cancers. However, the overall objective response rate of ICB therapy for various cancers remains insufficient. Hence, novel strategies a...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Fukushima Society of Medical Science
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694512/ https://www.ncbi.nlm.nih.gov/pubmed/37880140 http://dx.doi.org/10.5387/fms.23-00001 |